Novo Nordisk A/S (NVO) Financials: History & Chart

Novo Nordisk A/S (NVO)NVONovo Nordisk A/S

About Novo Nordisk A/S

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Bagsvaerd, CR

77,406 employees

www.novonordisk.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Maziar Mike Doustdar

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	51.21B	14.93B	12.42B	11.76B	12.11B	11.31B	11.86B	10.64B	9.80B
Cost of Goods Sold	9.30B	2.10B	2.38B	2.81B	2.02B	1.87B	1.80B	1.69B	1.48B
Gross Profit	41.91B	12.83B	10.04B	8.95B	10.08B	9.45B	10.06B	8.95B	8.32B
Gross Profit Margin	81.8%	86.0%	80.9%	76.1%	83.3%	83.5%	84.8%	84.1%	84.9%
Total Operating Expenses	18.75B	3.64B	5.06B	5.24B	4.81B	3.83B	4.97B	3.91B	4.59B
Research & Development	8.14B	1.59B	2.30B	2.41B	1.84B	1.49B	1.91B	1.42B	2.33B
Selling, General & Administrative	10.55B	2.04B	2.74B	2.80B	2.97B	2.33B	2.81B	2.48B	2.32B
Operating Income (EBIT)	23.16B	9.19B	4.98B	3.71B	5.27B	5.62B	5.08B	5.05B	3.73B
Operating Margin	45.2%	61.6%	40.1%	31.6%	43.5%	49.7%	42.9%	47.4%	38.1%
Income Before Tax (EBT)	24.28B	9.59B	5.36B	4.00B	5.33B	5.37B	4.92B	5.13B	3.65B
Interest Income	2.44B	933.37M	384.25M	287.73M	837.11M	496.28M	541.56M	206.39M	138.23M
Interest Expense	1.32B	539.55M	N/A	N/A	781.03M	751.02M	704.87M	122.52M	224.91M
Other Income/Expense	1.12B	393.83M	384.25M	287.73M	56.08M	-254.73M	-163.31M	83.87M	-86.68M
Net Income	19.02B	7.49B	4.22B	3.14B	4.18B	4.21B	3.91B	4.07B	2.89B
Income Tax Expense	5.26B	2.10B	1.14B	864.12M	1.15B	1.16B	1.01B	1.06B	760.56M
Net Profit Margin	37.1%	50.2%	34.0%	26.7%	34.5%	37.2%	32.9%	38.3%	29.5%
EBITDA	26.55B	9.74B	5.85B	4.93B	6.03B	6.18B	5.80B	5.37B	5.01B
EBITDA Margin	51.8%	65.2%	47.1%	41.9%	49.8%	54.6%	48.9%	50.4%	51.1%
Depreciation & Amortization	3.40B	545.25M	872.68M	1.22B	761.34M	554.97M	719.40M	320.84M	1.27B
EPS Basic	4.28	1.69	0.95	0.71	0.94	0.95	0.88	0.91	0.65
EPS Diluted	4.27	1.68	0.95	0.71	0.94	0.95	0.88	0.91	0.65
Shares Outstanding	4.44B	4.44B	4.45B	4.45B	4.45B	4.44B	4.45B	4.45B	4.46B
Diluted Shares Outstanding	4.45B	4.45B	4.45B	4.45B	4.45B	4.45B	4.46B	4.46B	4.47B

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	48.49B	40.19B	34.38B	25.39B	21.52B	20.79B	18.27B	17.18B
Cost of Goods Sold	9.22B	6.16B	5.29B	4.08B	3.62B	3.43B	3.01B	2.71B
Gross Profit	39.27B	34.03B	29.09B	21.31B	17.90B	17.37B	15.26B	14.47B
Gross Profit Margin	81.0%	84.7%	84.6%	83.9%	83.2%	83.5%	83.5%	84.2%
Total Operating Expenses	19.24B	16.27B	13.90B	10.58B	8.94B	8.50B	7.40B	7.21B
Research & Development	8.16B	6.65B	4.80B	3.45B	2.72B	2.53B	2.13B	2.27B
Selling, General & Administrative	11.03B	9.32B	9.12B	7.27B	6.28B	6.04B	5.36B	5.12B
Operating Income (EBIT)	20.03B	17.76B	15.18B	10.74B	8.96B	8.87B	7.86B	7.26B
Operating Margin	41.3%	44.2%	44.2%	42.3%	41.7%	42.6%	43.0%	42.2%
Income Before Tax (EBT)	20.48B	17.60B	15.49B	9.91B	9.03B	8.70B	7.27B	7.31B
Interest Income	199.11M	254.38M	158.23M	34.30M	35.31M	55.20M	9.73M	7.83M
Interest Expense	660.08M	226.98M	80.23M	54.24M	44.17M	63.88M	32.93M	13.06M
Other Income/Expense	452.19M	-158.88M	310.84M	-824.69M	66.64M	-163.14M	-588.32M	56.37M
Net Income	16.07B	13.98B	12.39B	7.97B	7.30B	6.90B	5.83B	5.93B
Income Tax Expense	4.41B	3.63B	3.11B	1.94B	1.73B	1.80B	1.44B	1.38B
Net Profit Margin	33.1%	34.8%	36.0%	31.4%	33.9%	33.2%	31.9%	34.5%
EBITDA	23.48B	20.41B	16.58B	11.79B	9.88B	9.81B	8.70B	7.86B
EBITDA Margin	48.4%	50.8%	48.2%	46.4%	45.9%	47.2%	47.7%	45.8%
Depreciation & Amortization	3.45B	2.64B	1.39B	1.06B	920.86M	942.34M	847.45M	602.88M
EPS Basic	3.62	3.14	2.76	1.76	1.59	1.48	1.23	1.23
EPS Diluted	3.61	3.13	2.76	1.75	1.58	1.48	1.23	1.22
Shares Outstanding	4.45B	4.45B	4.48B	4.53B	4.59B	4.67B	4.75B	4.84B
Diluted Shares Outstanding	4.45B	4.46B	4.49B	4.54B	4.61B	4.68B	4.76B	4.85B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.